|
1
|
Fisher B, Anderson S, Bryant J, Margolese
RG, Deutsch M, Fisher ER, Jeong JH and Wolmark N: Twenty-year
follow-up of a randomized trial comparing total mastectomy,
lumpectomy and lumpectomy plus irradiation for the treatment of
invasive breast cancer. N Engl J Med. 347:1233–1241. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Veronesi U, Cascinelli N, Mariani L, Greco
M, Saccozzi R, Luini A, Aguilar M and Marubini E: Twenty-year
follow-up of a randomized study comparing breast-conserving surgery
with radical mastectomy for early breast cancer. N Engl J Med.
347:1227–1232. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Komoike Y, Akiyama F, Iino Y, et al:
Ipsilateral breast tumor recurrence (IBTR) after breast-conserving
treatment for early breast cancer: Risk factors and impact on
distant metastases. Cancer. 106:35–41. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anderson SJ, Wapnir I, Dignam JJ, Fisher
B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP
and Wolmark N: Prognosis after ipsilateral breast tumor recurrence
and locoregional recurrences in patients treated by
breast-conserving therapy in five National Surgical Adjuvant Breast
and Bowel Project protocols of node-negative breast cancer. J Clin
Oncol. 27:2466–2473. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Whelan T, Clark R, Roberts R, Levine M and
Foster G: Investigators of the Ontario Clinical Oncology Group:
Ipsilateral breast tumor recurrence postlumpectomy is predictive of
subsequent mortality: Results from a randomized trial. Int J Radiat
Oncol Biol Phys. 30:11–16. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haffty BG, Reiss M, Beinfield M, Fischer
D, Ward B and McKhann C: Ipsilateral breast tumor recurrence as a
predictor of distant disease: Implications for systemic therapy at
the time of local relapse. J Clin Oncol. 14:52–57. 1996.PubMed/NCBI
|
|
7
|
Rauschecker H, Clarke M, Gatzemeier W and
Recht A: Systemic therapy for treating locoregional recurrence in
women with breast cancer. Cochrane Database Syst Rev.
4:CD0021952001.PubMed/NCBI
|
|
8
|
Waeber M, Castiglione-Gertsch M, Dietrich
D, Thürlimann B, Goldhirsch A, Brunner KW and Borner MM: Swiss
Group for Clinical Cancer Research (SAKK): Adjuvant therapy after
excision and radiation of isolated postmastectomy locoregional
breast cancer recurrence: Definitive results of a phase III
randomized trial (SAKK 23/82) comparing tamoxifen with observation.
Ann Oncol. 14:1215–1221. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aebi S, Gelber S, Anderson SJ, et al:
CALOR investigators: Chemotherapy for isolated locoregional
recurrence of breast cancer (CALOR): A randomised trial. Lancet
Oncol. 15:156–163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davies C, Godwin J, Gray R, et al: Early
Breast Cancer Trialists' Collaborative Group (EBCTCG): Relevance of
breast cancer hormone receptors and other factors to the efficacy
of adjuvant tamoxifen: Patient-level meta-analysis of randomised
trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peto R, Davies C, Godwin J, et al: Early
Breast Cancer Trialists' Collaborative Group (EBCTCG): Comparisons
between different polychemotherapy regimens for early breast
cancer: Meta-analyses of long-term outcome among 100,000 women in
123 randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Knowlden JM, Hutcheson IR, Jones HE,
Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson
RI: Elevated levels of epidermal growth factor receptor/c-erbB2
heterodimers mediate an autocrine growth regulatory pathway in
tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shou J, Massarweh S, Osborne CK, Wakeling
AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen
resistance: Increased estrogen receptor-HER2/neu cross-talk in
ER/HER2-positive breast cancer. J Natl Cancer Inst. 96:926–935.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Massarweh S, Osborne CK, Creighton CJ, Qin
L, Tsimelzon A, Huang S, Weiss H, Rimawi M and Schiff R: Tamoxifen
resistance in breast tumors is driven by growth factor receptor
signaling with repression of classic estrogen receptor genomic
function. Cancer Res. 68:826–833. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cardoso F, Costa A, Norton L, et al:
ESO-ESMO 2nd international consensus guidelines for advanced breast
cancer (ABC2). Breast. 23:489–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arnedos M, Drury S, Afentakis M, A'Hern R,
Hills M, Salter J, Smith IE, Reis-Filho JS and Dowsett M: Biomarker
changes associated with the development of resistance to aromatase
inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann
Oncol. 25:605–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Swain SM, Wilson JW, Mamounas EP, Bryant
J, Wickerham DL, Fisher B, Paik S and Wolmark N: Estrogen receptor
status of primary breast cancer is predictive of estrogen receptor
status of contralateral breast cancer. J Natl Cancer Inst.
96:516–523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Niikura N, Liu J, Hayashi N, Mittendorf
EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN
and Ueno NT: Loss of human epidermal growth factor receptor 2
(HER2) expression in metastatic sites of HER2-overexpressing
primary breast tumors. J Clin Oncol. 30:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
|
